Short answer
Merck & Co. (MRK) filed its fiscal 2024 10-K annual report with the SEC on Feb 25, 2025. It reported revenue of $64.2B (+6.7% year over year) and net income of $17.1B.
- Top risk flagged: U.S. and international patent disputes threaten market exclusivity for key products impacting revenue protections
FY2024 key financial metrics · XBRL
- Revenue
- $64.2B
- +6.7% YoY
- Net income
- $17.1B
- +4589.6% YoY
- EPS (diluted)
- $6.74
- +4714.3% YoY
- ROE
- 37.0%
- +36.0 pp YoY
- Operating cash flow
- $21.5B
- +65.1% YoY
Source: XBRL data from the Merck & Co. (MRK) FY2024 10-K on SEC EDGAR. USD.
Merck & Co. FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Global pharmaceutical company focused on innovative drug discovery, development, manufacturing, and commercialization
- New emphasis on immuno-oncology and ophthalmology: Acquisitions/license agreements for MK-2010 (bispecific PD-1/VEGF antibody), MK-4082 (oral GLP-1 receptor agonist), MK-1045 (bispecific antibody for B-cell diseases), EyeBio ($1.2B acquisition, MK-3000 tri-specific antibody), Harpoon ($765M immunotherapy acquisition)
- Strategic expansion through asset acquisitions in bispecific antibodies and T-cell engagers, enhancing oncology and ophthalmology pipeline engagement
- R&D expenses charges totaling approx. $3.46 billion in 2024 linked to major acquisitions and licenses, notably $1.35B for EyeBio acquisition and $750M for MK-1045 acquisition
- Capital expenditures $3.4B in 2024 with $20B planned 2024–2028, including $11B U.S. investments to expand oncology, vaccine, and animal health manufacturing capacity
Management Discussion & Analysis
- Revenue $64.2B in 2024, up 7% YoY ($60.1B in 2023), or 10% excluding foreign exchange impact
- Operating segments: Pharmaceutical (not quantified separately) and Animal Health (contributed to growth)
- Oncology led growth: Keytruda sales $29.5B (+18% YoY, +22% ex-FX), Lynparza alliance revenue $1.3B (+9%), Welireg sales $509M (>100%)
- U.S. sales $32.3B (+13%), International sales $31.9B (+1%, +6% ex-FX); FX headwind from Argentine peso devaluation
- Capital returned to shareholders $9.1B: $7.8B dividends, $1.3B buybacks; new $10B share repurchase authorized in Jan 2025
- Quarterly dividend raised to $0.81 per share from $0.77 in Nov 2024
- Management highlights pipeline expansion, new product launches Winrevair and Capvaxive, and business development acquisitions
- Pricing pressures from U.S. healthcare reforms and Inflation Reduction Act with expected negative impact on future pricing and profits
Risk Factors
- U.S. and international patent disputes threaten market exclusivity for key products impacting revenue protections
- Significant sales decline expected for Gardasil/Gardasil 9 vaccine in China in 2025 following lower 2024 sales
- Manufacturing delays for certain products, including vaccines, disrupt supply and could impact revenue streams
- Intense competition from lower-cost generic and biosimilar products pressures pricing and market share
- Increasing cyber-attacks on sophisticated software and cloud infrastructure risking disruption of global operations
Generated from the filing text; verify against the original. How to read a 10-K
Other Merck & Co. annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.